By Sheri Kasprzak
New York, Oct. 31 - Cel-Sci Corp. said it secured up to $5 million from an equity line of credit.
Under the terms of the two-year agreement, Cel-Sci may sell shares to the investor at an 11% discount to market.
Based in Vienna, Va., Cel-Sci develops novel treatments for cancer and infectious diseases.
| Issuer: | Cel-Sci Corp.
|
| Issue: | Equity line of credit
|
| Amount: | $5 million
|
| Price: | 11% discount to market
|
| Tenor: | Two years
|
| Warrants: | No
|
| Settlement date: | Oct. 31
|
| Stock price: | $0.51 at close Oct. 31
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
